- Home
- LDWY vs TSBX Comparison
LDWY vs TSBX Comparison
Compare LDWY & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- TSBX
- Stock Information
- Founded
- LDWY 1990
- TSBX 2015
- Country
- LDWY United States
- TSBX United States
- Employees
- LDWY N/A
- TSBX N/A
- Industry
- LDWY Advertising
- TSBX
- Sector
- LDWY Consumer Discretionary
- TSBX
- Exchange
- LDWY Nasdaq
- TSBX Nasdaq
- Market Cap
- LDWY 9.2M
- TSBX 7.7M
- IPO Year
- LDWY 1991
- TSBX 2023
- Fundamental
- Price
- LDWY $4.90
- TSBX $0.36
- Analyst Decision
- LDWY
- TSBX Buy
- Analyst Count
- LDWY 0
- TSBX 3
- Target Price
- LDWY N/A
- TSBX $4.75
- AVG Volume (30 Days)
- LDWY 6.5K
- TSBX 706.4K
- Earning Date
- LDWY 08-18-2025
- TSBX 08-13-2025
- Dividend Yield
- LDWY N/A
- TSBX N/A
- EPS Growth
- LDWY N/A
- TSBX N/A
- EPS
- LDWY N/A
- TSBX N/A
- Revenue
- LDWY $42,183,000.00
- TSBX N/A
- Revenue This Year
- LDWY N/A
- TSBX N/A
- Revenue Next Year
- LDWY N/A
- TSBX N/A
- P/E Ratio
- LDWY N/A
- TSBX N/A
- Revenue Growth
- LDWY 425.12
- TSBX N/A
- 52 Week Low
- LDWY $3.02
- TSBX $0.29
- 52 Week High
- LDWY $5.53
- TSBX $3.00
- Technical
- Relative Strength Index (RSI)
- LDWY 50.82
- TSBX 44.06
- Support Level
- LDWY $4.85
- TSBX $0.35
- Resistance Level
- LDWY $5.12
- TSBX $0.38
- Average True Range (ATR)
- LDWY 0.16
- TSBX 0.03
- MACD
- LDWY -0.05
- TSBX -0.00
- Stochastic Oscillator
- LDWY 7.84
- TSBX 3.67
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.